Kate Vaughan

Kate Vaughan

Auto-generated profile, based on publicly available information

Kate Vaughan

Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2014 in Measurement Science and Technology
Verified
Journal Article
Open access
NMN D McGuire
N D McGuire
RER J Ewen
R J Ewen
BCBen De Lacy Costello
Ben De Lacy Costello
CGC E Garner
C E Garner
CPChris Probert
Chris Probert
Norman RatcliffeNorman Ratcliffe
Norman Ratcliffe
Rapid volatile profiling of stool sample headspace was achieved using a combination of short multi-capillary chromatography column (SMCC), highly sensitive heated metal oxide semiconductor (MOS) sensor and artificial neural network (ANN) software. For direct analysis of biological samples this prototype offers alternatives to conventional GC detectors and electronic nose technology. The performance was compared to an identical instrument incorporating a long single capillary column (LSCC). The ability of the prototypes to separate complex mixtures was assessed using gas standards and homogenised in house ‘standard’ stool samples, with both capable of detecting more than 24 peaks per sample. The elution time was considerably faster with the SMCC resulting in a run time of 10 minutes compared to 30 minutes for the LSCC.

13 May 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
LCLindsay Esther Carnie
Lindsay Esther Carnie
ALAngela Lamarca
Angela Lamarca
KVKate Vaughan
Kate Vaughan
ZKZainul Abedin Kapacee
Zainul Abedin Kapacee
LMLynne McCallum
Lynne McCallum
JVJuan Valle
Juan Valle
Introduction Pancreatic exocrine insufficiency (PEI) in patients with pancreatic malignancy is well documented in the literature and is known to negatively impact on overall survival and quality of life. A lack of consensus opinion remains on the optimal diagnostic test that can be adapted for use in a clinical setting for this cohort of patients. This study aims to better understand the prevalence of PEI and the most suitable diagnostic techniques in patients with advanced pancreatic malignancy. Methods and analysis This prospective observational study will be carried out in patients with pancreatic malignancy (including adenocarcinoma and neuroendocrine neoplasms). Consecutive patients with inoperable pancreatic malignancy referred for consideration of first-line chemotherapy will be considered for eligibility. The study comprises three cohorts: demographic cohort (primary objective to prospectively investigate the prevalence of PEI in patients with inoperable pancreatic malignancy); sample size 50, diagnostic cohort (primary objective to design and evaluate an optimal diagnostic panel to detect PEI in patients with inoperable pancreatic malignancy); sample size 25 and follow-up cohort (primary objective to prospectively evaluate the proposed PEI diagnostic panel in a cohort of patients with inoperable pancreatic malignancy); sample size 50. The following is a summary of the protocol and methodology. Ethics and dissemination Full ethical approval has been granted by the North West Greater Manchester East Research and Ethics Committee, reference: 17/NW/0597. This manuscript reflects the latest protocol V.8 approved 21 April 2020. Findings will be disseminated by presentation at national/international conferences, publication in peer-review journals and distribution via patient advocate groups. Trial registration number 194255, NCT0361643.